Χώρα: Αυστραλία
Γλώσσα: Αγγλικά
Πηγή: Department of Health (Therapeutic Goods Administration)
ceftazidime pentahydrate, Quantity: 1164.8 mg (Equivalent: ceftazidime, Qty 1 g)
Fresenius Kabi Australia Pty Ltd
ceftazidime pentahydrate
Injection, powder for
Excipient Ingredients: sodium carbonate
Intramuscular, Intravenous Bolus
5, 10, 1
(S4) Prescription Only Medicine
Ceftazidime is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. Indications include: - Sever infections in general: for expample septicaemia (including neonatal sepsis), bacteraemia, patients in intensive care units with specific problems, e.g infected burns. - Respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis, bronchitis. - Sever ear, nose and throat infections: for example, otitis media, mastoiditis. - Urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), infections associated with bladder and renal stones. - Skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. - Gastrointestinal and abdominal infections: for example, Intra-abdominal abscesses, enterocolitis. - Bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.
Visual Identification: Sterile, white to pale yellow powder; Container Type: Vial; Container Material: Glass Type II Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Licence status A
2015-07-02
Page 1 of 3 CEFTAZIDIME KABI Ceftazidime (as pentahydrate) CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Ceftazidime Kabi. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Ceftazidime Kabi against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT CEFTAZIDIME KABI IS USED FOR Ceftazidime Kabi is used to treat a wide range of infections caused by bacteria. These infections may affect the chest (bronchitis or pneumonia), ears, nose, throat, bladder and urinary tract, skin and soft tissue, stomach or bones. This medicine belongs to a group of medicines called cephalosporins. It works by killing the bacteria that cause these infections. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED FOR YOU. Your doctor may have prescribed it for another reason. Ceftazidime Kabi is available only with a doctor's prescription. Ceftazidime Kabi is not addictive. BEFORE YOU ARE GIVEN CEFTAZIDIME KABI _WHEN YOU MUST NOT BE GIVEN IT _ YOU MUST NOT BE GIVEN CEFTAZIDIME KABI IF YOU HAVE EVER HAD AN ALLERGIC REACTION TO: • any medicine containing cephalosporins or penicillins • any of the ingredients listed at the end of this leaflet. Some of the symptoms of an allergic reaction may include shortness of breath; wheezing or difficulty breathing; swelling of the face, lips, tongue or other parts of the body; rash, itching or hives on the skin. YOU MUST NOT BE GIVEN THIS MEDICINE AFTER THE EXPIRY DATE PRINTED ON THE PACK OR IF THE PACKAGING IS TORN OR SHOWS SIGNS OF TAMPERING. IF YOU ARE NOT SURE WHETHER YOU SHOULD BE GIVEN THIS MEDICINE, TALK TO YOUR DOCTOR. _BEFORE YOU ARE GIVEN IT _ TELL YOUR DOCTOR IF YOU HAVE ALLERGIES TO ANY OTHER MEDIC Διαβάστε το πλήρες έγγραφο
AUSTRALIAN PRODUCT INFORMATION- CEFTAZIDIME KABI (CEFTAZIDIME AS PENTAHYDRATE) Page 1 of 14 1 NAME OF MEDICINE Ceftazidime (as pentahydrate) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION CEFTAZIDIME KABI powder for injection contains either 1 g or 2 g of ceftazidime (as pentahydrate). Ceftazidime Kabi contains approximately 52.5 mg (2.3 mEq) of sodium per gram of ceftazidime. 1.164g ceftazidime pentahydrate is equivalent to 1 g ceftazidime free acid. For the full list of excipients, see SECTION 6.1 LIST OF EXCIPIENTS. 3 PHARMACEUTICAL FORM Powder for injection. Supplied as a white to pale yellow powder. On the addition of Water for Injections, Ceftazidime Kabi dissolves with effervescence to produce a solution for injection. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ceftazidime is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. Indications include: SEVERE INFECTIONS IN GENERAL: for example septicaemia (including neonatal sepsis), bacteraemia, patients in intensive care units with specific problems, e.g. infected burns. RESPIRATORY TRACT INFECTIONS: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis, bronchitis. SEVERE EAR, NOSE AND THROAT INFECTIONS: for example, otitis media, mastoiditis. URINARY TRACT INFECTIONS: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), infections associated with bladder and renal stones. SKIN AND SOFT TISSUE INFECTIONS: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. GASTROINTESTINAL AND ABDOMINAL INFECTIONS: for example, intra-abdominal abscesses, enterocolitis. BONE AND JOINT INFECTIONS: for example, osteitis, osteom Διαβάστε το πλήρες έγγραφο